Αρχική World News A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable... World News A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC Από Ogkologos - 29 Ιανουαρίου, 2025 846 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Por qué la Reunión Anual de la American Society of Clinical... 1 Ιουνίου, 2021 Professor Eithne Costello: On the road to early detection 12 Νοεμβρίου, 2021 Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients... 7 Μαΐου, 2026 FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax... 3 Ιουνίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Can’t Sleep? Tips for Coping with Insomnia New on NCI Websites for July 2019 John Cena Set The Record For Most Make-A-Wish Visits And He... EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in...
